Colloids and surfaces. B, Biointerfaces
Esterase-activatable dimeric HDAC inhibitor nanotherapeutics for enhanced lymphoma epigenetic therapy.
Tongyu Li, Wanchuan Zhuang, Shufang Fan, Ping Yi, Guifang Ouyang, Wenbin Qian
Published: 202610.1016/j.colsurfb.2026.115416
Abstract
BACKGROUND: Despite advances in lymphoma therapy, significant challenges persist including R-CHOP resistance and CAR-T toxicity. Hydroxamate-based histone deacetylase inhibitors (HDACi) like vorinostat (SAHA) offer epigenetic therapeutic potential bu…
Preview only. Read the full abstract at the source